Expression of Metallothioneins in Cutaneous Squamous Cell Carcinoma and Actinic Keratosis

Aleksandra Zamirska · Łukasz Matusiak · Piotr Dziegiel · Grażyna Szybejko-Machaj · Jacek C. Szepietowski

Received: 31 October 2011 / Accepted: 28 February 2012 / Published online: 10 March 2012
© The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract Metallothioneins (MT) are low-molecular weight proteins implicated in heavy metal detoxification, zinc and cooper homeostasis and cell protection against free radicals. In variety of cancers MT-overexpression was shown, but there are just a few studies on the role of MT in skin carcinogenesis. Current study was undertaken to evaluate MT and Ki-67 expression in pre-cancerous skin lesions as well as in fully developed skin cancers. 73 squamous cell carcinomas (SCC), 23 actinic keratoses (AK) and 20 normal skin samples were included in the study. In obtained paraffin sections immunohistochemical reactions were performed. MT-expression in SCC (mean 2.89±1.83) was significantly higher than in AK (mean 1.69±1.26) (p=0.006) and higher than in normal skin (mean 2±0.79) (p=0.0075). The MT-expression positively correlated with Ki-67 expression (R=0.28; p=0.017) in SCC and in AK (R=0.49; p=0.018). Various clinico-pathological variables, e.g. morphology, size of lesions and the depth of neoplastic infiltration were not associated to MT-expression in both SCC and AK. The grade of histological differentiation of SCC correlated positively with Ki-67 antigen (p<0.001) and did not correlate with MT-expression (p=0.06). Ki-67 expression was higher in SCC and in AK than in healthy skin (p=0.003). In SCC and in AK expression of Ki-67 antigen correlated positively with MT-expression (respectively p=0.017 and p=0.018). MT may serve as a good markers of proliferation in SCC and AK. MT-overexpression in SCC may suggest a potential role of MT in skin carcinogenesis.

Keywords Metallothioneins · Squamous cell carcinoma · Actinic keratosis · Ki-67 · Skin

Introduction

Metallothioneins (MT I-IV), small cysteine-rich, metal-binding proteins, have been described in number of organs, including the skin [1, 2]. High levels of MT-I and II, the most widely expressed isoforms, are found in liver, kidneys and skin, MT-III is predominantly expressed in brain, while MT-IV has been identified in squamous epithelia of alimentary tract [3–5]. In stratified squamous epithelia MT I and II were expressed in the basal layer, whereas MT IV was discovered in the differentiating spinous layer [5].

The main function of MT is their contribution in zinc and copper homeostasis in cells and tissues. These metallic ions, being the part of proteins and enzymes (e.g. zinc-dependent transcription factors or p53 protein), are crucial for proper cell metabolism and differentiation [2, 6]. Although, MT serve as antioxidants and protect cells’ structures against free radicals and toxic influence of heavy metal ions (Cd, Pb, Ni, Hg) [7, 8], they also have proliferative, antiapoptotic and angiogenic potential, what explains their role in oncogenesis and tumor progression [2, 9–11]. MT overexpression was revealed in variety of human tumors. In many of
them a positive correlation between MT overexpression and aggressive clinical behaviour as well as poorer prognosis has been found (e.g. for carcinomas of urinary and digestive tract, breast cancers, lung carcinomas, squamous cell carcinomas of oral cavity and larynx as well as malignant melanoma) [1, 12–21]. Some researchers [15, 17, 18] suggested that less differentiated, anaplastic tumor cells were linked to higher MT expression, indicating for MT as a potential and important prognostic factor. Moreover, it was also proved that the overexpression of MT in tumor cells was responsible for the development of resistance to anticancer drugs and radiotherapy [9, 22].

Excessive exposure to ultraviolet radiation (UV) plays the main role in etiopathogenesis of actinic keratosis (AK) and squamous cell carcinoma (SCC) [23, 24]. UV causes increase in reactive oxidative species (ROS) leading to DNA damage [25]. Due to high level of free radicals, keratinocytes enhance synthesis of endogenous antioxidants, including MT. The role and behaviour of MT in skin carcinogenesis still remain unclear. It should be kept in mind, that AK being a part of a multi-step carcinogenesis process represents an early stage in a continuum that leads from carcinoma in situ to invasive SCC [26–28]. Therefore, the current study was undertaken to evaluate MT expression in SCC as well as in AK. The aim of the study was also to estimate the eventual relationships between MT expression and the expression of Ki-67 antigen as well as some clinical parameters, including the type of the tumor.

Materials and Methods

The material consisted of 96 fair-skin biopsies obtained from 73 patients with SCC (mean age of 73.6±14.2 years) and 23 subjects suffering from AK (mean age of 71.4±11.2 years). The mean duration of the disease was assessed as 23.0±42.4 months for SCC (range, 1–240 months) and 27.6±17.7 months for AK (range, 6–84 months). The characteristics of the studied group is given in the Tables 1. Twenty samples of clinically unchanged, but sun-exposed skin, taken from healthy volunteers (mean age of 57.3±18.5 years) during plastic surgery procedures, served as a control. The study was approved by the Ethics Committee of Wroclaw Medical University (protocol number-KB 609/2007).

Tissue samples were immersed in 10 % buffered formalin and embedded in paraffin blocks. Alternate sections were stained with hematoxylin and eosin and used for further histological analysis. Two of us, with experience in dermatopathology, reviewed all the specimens independently (AZ and GSM). The histological grade of malignancy in SCC samples was determined using the Broders' classification based on the degree of differentiation and keratinization of tumor cells [29]. Moreover, for each tumor the degree of keratinization, nuclear polimorphism, the invasion level after Clark [30], density and depth of lymphocytes infiltration were evaluated and graded as well (Table 2). The samples of AK were devided in 3 groups taking under consideration the histological features (1 bowenoid, 8 hypertrophic and 14 of atrophic types).

Immunohistochemistry

Immunohistochemistry was carried out with the monoclonal antibody E9 (code M0639), which binds specifically MT-I and MT-II, using a 1:100 dilution for MT and the monoclonal antibody MIB-1 (code M7240) diluted 1:50 for Ki-67 antigen (Dako, Denmark). Four-micrometer-thick tissue sections were deparaffinized by xylene bath followed by bath with 100 %, 96 % and 70 % ethanol for 5 min. Slides were then pretreated by heating citrate buffer in a steamer and then cooled for 15 min. To block endogenous peroxidase activity 3 % H2O2 was added. Next the slides were rinsed by heating citrate buffer in a steamer and then cooled for 15 min. To block endogenous peroxidase activity 3 % H2O2 was added. Next the slides were rinsed in PBS for 5 min. Afterwards the primary antibody was added and slides were incubated 18 h at 4°C and washed in 3 changes of PBS. The sections were then incubated with biotinylated anti-mouse immunoglobulin for 20 min, washed again in 3 changes of PBS before being incubated with streptavidin–peroxidase complex for 20 min. The slides were visualized with diaminobenzidine chromogen (DAB) for 5 min. Finally they were placed into distilled water, stained with hematoxylin and closed with coverslips.

### Table 1 The characteristics of the studied group

| Clinical parameters | Number of patients with SCC | % | Number of patients with AK | % |
|---------------------|----------------------------|---|----------------------------|---|
| Age                 | < 60 years                 | 8 | 11                         | 4 | 17 |
|                     | 60–80 years                | 43 | 59                        | 15 | 66 |
|                     | > 80 years                 | 22 | 30                        | 4 | 17 |
| Gender              | women                      | 29 | 40                        | 18 | 78 |
|                     | men                        | 44 | 60                        | 5 | 22 |
| Size                | < 2 cm                     | 46 | 63                        | 19 | 83 |
|                     | 2–5 cm                     | 23 | 31,5                      | 4 | 17 |
|                     | > 5 cm                     | 4 | 5,5                       | 0 | 0 |
| Localization        | Face                       | 39 | 53                        | 14 | 61 |
|                     | Lip                        | 13 | 18                        | 2 | 9 |
|                     | Ear                        | 12 | 16                        | 1 | 9 |
|                     | Scalp                      | 2 | 3                         | 0 | 0 |
|                     | Trunk                      | 0 | 0                         | 1 | 4 |
|                     | Upper limb                 | 2 | 3                         | 0 | 0 |
|                     | Lower limb                 | 5 | 7                         | 5 | 22 |
| Morphology          | Hyperkeratotic             | 50 | 68                       | 15 | 65 |
|                     | Exulcerans                 | 22 | 30                        | - | - |
|                     | Vegetans                   | 1 | 2                         | - | - |
|                     | Erythematous               | - | -                         | 8 | 35 |
Slides were assessed in magnification of 100x and 200x and digitally imaged. For the evaluation of the MT expression semiquantitative Remmele scale was used (Table 3) [31]. The method takes into account both the intensity of the color reaction and the percentage of positive cells in each lesion. The final score (IRS) represents the product of these 2 values, ranging from 0 to 12 points: no reaction 0 pts., weak reaction 1–2 pts., moderate reaction 3–4 pts., intense reaction 6–12 pts. Expression of Ki-67 was also evaluated semiquantitatively by percent of immunopositive cells including the following intervals: 0 % (0 pts.), 1–10 % (1 pts.), 11–25 %, (2 pts.), 26–50 % (3 pts.) and above 50 % (4 pts.). The localization and distribution of staining within the normal skin, in AK and SCC has been studied as well.

Statistical Analysis

All data were analyzed statistically with Statistica® 7.1 software (Statsoft, Cracow, Poland). Student’s t-test for independent variables, Mann–Whitney U test, univariate analysis of variance with post hoc test and \( \chi^2 \) test were used where appropriate. Correlations between parameters were measured with Spearman’s rank correlation test. Results with p-values less than 0.05 were treated as statistically significant.

Results

All the healthy skin sections, 21 cases out of AKs (92 %) and 69 cases out of SCCs (95 %) showed MT-immunoreactivity. Significant differences were observed in localization of MT-positive cells in normal skin, in AK and in SCC (\( p < 0.01 \)). In healthy skin MT-expression was revealed in epidermal basal layer, hair matrix cells and outer hair root sheath, some cells of sebaceous and eccrine glands. In AK, MT-positive cells were found mostly in basal and parabasal layers of atypical epidermis (83 % AK). In well-differentiated SCCs (Broders 1–2) expression of MT was found in the periphery of tumor nest (61 % of cases), while in poorly differentiated SCCs (Broders 3–4) MT-positive cells were dispersed throughout the entire tumors (67.5 % cases) (Fig. 1a-d).

The MT expression in SCC was significantly higher than for AK (\( p = 0.006 \)) and higher than in normal skin (\( p = 0.07 \)); no differences in MT-expression between AK and normal skin were found (\( p = 0.81 \)) (Fig. 2). Ki-67 antigen was detected in 18 cases out of normal skin (90 %) and in all samples of SCC and AK. With regard to its immunostaging, the Ki-67 antigen was significantly higher expressed in SCC and in AK (with no difference between SCC and AK) than in healthy skin (\( p = 0.0025 \)) (Fig. 2).

| Table 2 | The histological parameters of evaluated SCC |
|---------|---------------------------------------------|
| **Histological parameters** | **Number of patients with SCC** | **%** |
| Broders | G1 (>75 % of keratinized cells) | 14 | 19 |
| | G2 (50–75 % of keratinized cells) | 19 | 26 |
| | G3 (25–50 % of keratinized cells) | 25 | 34 |
| | G4 (< 25 % of keratinized cells) | 15 | 21 |
| Depth of neoplastic infiltration according Clark scale | I- invasion into the epidermis | 0 | 0 |
| | II- invasion into the papillary dermis | 1 | 1 |
| | III- invasion to the junction of the papillary and reticular dermis | 4 | 5 |
| | IV- invasion into the reticular dermis | 29 | 40 |
| | V- invasion into the subcutaneous fat | 39 | 54 |
| Density of inflammatory infiltration around SCC | Mild inflammatory infiltration | 19 | 26 |
| | Moderate inflammatory infiltration | 40 | 55 |
| | Massive inflammatory infiltration | 14 | 19 |
| Depth of inflammatory infiltration | Dermis | 18 | 25 |
| | Subcutis | 55 | 75 |

| Table 3 | Immunoreactive Score (IRS) according to Remmele [31] |
|---------|-------------------------------------------------|
| **Percentage of positive cells** | **Intensity of stain** |
| 0 No positive cells | 0 No detectable stain |
| 1 1–10 % | 1 Weak nuclear stain |
| 2 11–50 % | 2 Moderate nuclear stain |
| 3 51–80 % | 3 Strong nuclear stain |
| 4 >80 % | |
The positive correlation between expression of MT and the expression of Ki-67 antigen was found in SCC as well as in AK, however the correlation with an AK lesions was stronger than with SCC ($R=0.28; p=0.017$ and $R=0.49; p=0.018$, respectively) (Fig. 3a, b). Such a phenomenon was absent in normal skin ($R=-0.07; p=0.76$). The mentioned above weak correlation between MT and Ki-67 in SCCs had its reflection in relationships with Broders’ grading (G) of histological differentiation of SCC. Contradictory to significant positive correlation between Ki-67 antigen and the tumour’s G ($R=0.4; p<0.001$), the MT-expression revealed only weak correlation with tendency to increase in poorly differentiated SCC ($R=0.2; p=0.06$).

Moreover, various clinico-pathological variables, including age, gender of patients, localization, morphology and size of the lesions, as well as the depth of neoplastic infiltration and the density and depth of inflammatory infiltration did not affect MT-expression in both SCC and AK.
Discussion

Only a few studies have been conducted to investigate the localization and the expression of MT in normal and neoplastic keratinocytes. It has been reported that in healthy skin MT are rather poorly expressed and restricted to basal and suprabasal layers [5, 32, 33] what was confirmed also in the present study. The same situation occurred in most AK lesions—MT expression was observed only in basal and spinous layers. In well-differentiated SCC the MT were detected predominantly in the periphery of tumor nest, while in poorly differentiated squamous cell carcinomas MT positive cells were dispersed throughout the entire tumor. Similar pattern of MT immunostaining has been noticed by other researches in SCC of skin and tongue [34, 35]. Additionally, head and neck cancers as well as breast adenocarcinomas have shown MT expression in healthy tissues surrounding the tumors [36, 37]. In the epithelium adjacent to SCC, the intense MT labeling of suprabasal layer was detected, what suggests that migrating tumor cells may induce MT-synthesis in healthy tissue adjacent to the tumor [34, 36].

It has been found, that epidermal MT-expression is independent on clinico-pathological factors like age and gender of patients, duration of the disease and size, type or localization of cutaneous SCC. In addition the depth of neoplastic infiltration as well as density and depth of inflammatory infiltration around SCC did not influence MT-expression. Similar observations were made by Borges et al. in non-melanoma skin cancers (NMSC) [34]. In their study no significant correlation between MT-expression and size of tumor, time of the disease or age of patients has been found either [34].

Various tumor parameters have been studied to predict the course of SCC. The worse prognosis was linked to: tumor size (T>2 cm), type of precancerous lesion, localization, ulceration, immunosuppression, tumor thickness (>6 mm), G grading, the depth of tumor infiltration according to Clark’s scale, histological tumor type and perineural invasion [30, 38, 39]. Some laboratory based methods were found to be useful as well. The invasiveness of SCC (and BCC) was correlated with level of MMP-1 (matrix metalloproteinase 1) and adhesion molecule CD44v6 [40]. Goldman et al. [38] demonstrated that a combination of tumor thickness and the expression of cathepsin D may have a high predictive value. It was also noticed that the differentiation of SCC was correlated with Ki-67 index [40]. In this study the grade of histological differentiation correlated positively with Ki-67 antigen in SCC and did not correlate with MT-expression, however the tendency to an increase of MT-expression in poorly differentiated SCC was observed. Perhaps the analysis of a larger group of patients would bring unequivocal finding and MT-expression would become the next good marker of SCC malignancy. Similar observation was made by Muramatsu et al. [37] in oral and pharyngeal SCC, where MT positive cell index was adequately higher in poorly differentiated SCC than in well and moderately differentiated SCC.

It was noticed that epidermal MT-expression is independent on clinico-pathological factors like age and gender of patients, duration of the disease and size, type or localization of cutaneous SCC. In addition the depth of neoplastic infiltration as well as density and depth of inflammatory infiltration around SCC did not influence MT-expression. Similar observations were made by Borges et al. in non-melanoma skin cancers (NMSC) [34]. In their study no significant correlation between MT-expression and size of tumor, time of the disease or age of patients has been found either [34].

Various tumor parameters have been studied to predict the course of SCC. The worse prognosis was linked to: tumor size (T>2 cm), type of precancerous lesion, localization, ulceration, immunosuppression, tumor thickness (>6 mm), G grading, the depth of tumor infiltration according to Clark’s scale, histological tumor type and perineural invasion [30, 38, 39]. Some laboratory based methods were found to be useful as well. The invasiveness of SCC (and BCC) was correlated with level of MMP-1 (matrix metalloproteinase 1) and adhesion molecule CD44v6 [40]. Goldman et al. [38] demonstrated that a combination of tumor thickness and the expression of cathepsin D may have a high predictive value. It was also noticed that the differentiation of SCC was correlated with Ki-67 index [40]. In this study the grade of histological differentiation correlated positively with Ki-67 antigen in SCC and did not correlate with MT-expression, however the tendency to an increase of MT-expression in poorly differentiated SCC was observed. Perhaps the analysis of a larger group of patients would bring unequivocal finding and MT-expression would become the next good marker of SCC malignancy. Similar observation was made by Muramatsu et al. [37] in oral and pharyngeal SCC, where MT positive cell index was adequately higher in poorly differentiated SCC than in well and moderately differentiated SCC.

MT are engaged in cells proliferation and differentiation. In present study a positive correlation between MT-expression and Ki-67 expression has been described in AK and in SCC, which may testify the participation of both proteins in intense neoplastic proliferation of keratinocytes. The same correlation was found in colon adenocarcinoma and nosopharyngeal carcinoma [41, 42].

Many studies have proved that MT-expression is higher in cancers in comparison to precancerous lesions. It was observed in laryngeal and nosopharyngeal carcinomas [42, 43] and may result from higher demand for endogenous zinc and higher proliferative activity of the neoplastic cells. In the current research the MT-expression was also significantly higher in cancers in comparison to precancerous lesions.
higher in SCC than in AK and higher than in normal skin. Moreover, it has been described by other authors, that a higher MT-expression in NMSC is associated with tumoral aggressiveness. Borges et al. [34] analyzed the differences in MT-expression in BCC and SCC. In basal cell carcinomas MT-expression was observed in 18.5%±21.2% of tumor cells, while for squamous cell carcinomas immunostaining indices were 69.1±14.4% [34]. Similar conclusion was by Rossen et al. [44], who have examined MT-expression in different types of BCC and found that the immunoreactivity was high in infiltrating/morphea-like BCC, while most nodular BCC, which have less aggressive clinical behaviour, showed decreased or absent of MT-immunostaining [44].

The knowledge of the mechanism responsible for neoplastic transformation of keratinocytes gives an opportunity to create new diagnostic and therapeutic methods. In our study we have observed a high expression of Ki-67 antigen in AK and SCC as well, while MT-expression was statistically higher in SCC in comparison to its in AK lesions. A confrontation of those two values could serve as a helpful diagnostic method for differentiation of SCC from AK in doubtful cases.

To the best of our knowledge, our study is the first one comparing the MT-expression in cutaneous SCC and AK. Moreover, for the first time we showed correlation between expression of MT and Ki-67 antigen in cutaneous SCC and AK. In summary, based on our own results, it seems that MT-overexpression in SCC is an unfavorable factor promoting cutaneous carcinogenesis. This theory requires further investigations. Perhaps the antioxidative function and anti-immunosuppressive effect of metallothioneins prevail over their proliferative and anti-apoptotic properties in healthy skin, while MT-overexpression in neoplastic epidermal keratinocytes may lead to worsening course of the disease.

Acknowledgements This study was supported by the research grant provided by Foundation for Development of Polish Pharmacy and Medicine.

Funding Sources This study was supported by the research grant provided by Foundation for Development of Polish Pharmacy and Medicine.

Conflict of Interest Disclosure The authors have no conflict of interest to declare.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Dziegiel P (2004) Expression of metallothioneins in tumor cells. Pol J Pathol 55:3–12
2. Pedersen MO, Larsen A, Stoltenberg M et al (2009) The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 44:29–64
3. Coyle P, Philcox JC, Carey LC et al (2002) Metallothionein: the multipurpose protein. Cell Mol Life Sci 59:627–47
4. Palmiter RD, Findley SD, Whitmore TE et al (1992) MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci USA 89:6333–7
5. Quaife CJ, Findley SD, Erickson JC et al (1994) Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry 33:7250–9
6. Miles AT, Hawksworth GM, Beattie JH et al (2000) Induction, regulation, degradation and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol 35:35–70
7. Dziegiel P, Jelen M, Muszczynska B et al (2004) Role of metallothionein expression in non-small cell lung carcinomas. Roz Akad Med Bialymst 49:43–45
8. Sato M, Kondoh M (2002) Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals. Tohoku J Exp Med 196:9–22
9. Dutsch-Wicherek M, Sikora J, Tomaszewska R (2008) The possible biological role of metallothionein in apoptosis. Front Biosci 13:4029–38
10. Miyashita H, Sato Y (2005) Metallothionein 1 is a downstream target of vascular endothelial zinc finger 1 (VEZF1) in endothelial cells and participates in the regulation of angiogenesis. Endothelium 12:163–170
11. Nielsen AE, Bohr A, Penkowa M (2007) The balance between life and death of cells: roles of metallothioneins. Biomarker Insights 2:99–111
12. Brown JJ, Xu H, William-Smith L et al (2003) Evaluation of metallothionein and p53 expression as potential prognostic markers for laryngeal squamous cell carcinoma. Cell Mol Biol. 49 Online Pub:OL473-9
13. Cardoso SV, Silveira-Júnior JB, De Carvalho Machado V et al (2009) Expression of metallothionein and p53 antigens are correlated in oral squamous cell carcinoma. Anticancer Res 29:1189–93
14. Hishikawa Y, Koji T, Dhar DK et al (1999) Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer 81(4):712–20
15. Jin R, Bay BH, Chow VT et al (2001) Metallothionein 1 F mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Res Treat 66(3):265–72
16. Mitropoulos D, Kyroudi-Voulgari A, Theocharis S et al (2005) Prognostic significance of metallothionein expression in renal cell carcinoma. World J Surg Oncol 3:5
17. Ohshio G, Inamura T, Okada N et al (1996) Immunohistopathological study of metallothionein in pancreatic carcinomas. J Cancer Res Clin Oncol 122:351–5
18. Saga Y, Hashimoto H, Yachiku S et al (2002) Immunohistochecmical expression of metallothionein in human bladder cancer: correlation with histopathological parameters and patient survival. J Urol 168:2227–2231
19. Sens MA, Somji S, Garrett SH et al (2001) Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. Am J Pathol 159:21–26
20. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J et al (2008) Prognostic significance of nuclear and cytoplasmic expression of metallothioneins as related to proliferative activity in squamous cell carcinoma. Histol Histopathol 23(7):843–851
21. Weinlich G, Eisenk R, Hassler E et al (2006) Metallothionein overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer 94:835–41
22. Kelley SL, Basu A, Teicher BA et al (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813–15
23. Cohn BA (2000) From sunlight to actinic keratosis to squamous cell carcinoma. J Am Acad Dermatol 42:143–4
24. Oughtit A, Ananthaswamy HN (2001) A model for UV-induction of skin cancer. J Biomed Biotechnol 1:5–6
25. Nouri K (2007) Skin cancer. Mc Graw Hill Professional
26. Ackerman AB (2003) Solar keratosis is squamous cell carcinoma. Arch Dermatol 139:1216–17
27. Anwar J, Wrone DA, Kimyai-Asadi A et al (2004) The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol 22:189–96
28. Cockerell CJ, Wharton JR (2005) New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma). J Drugs Dermatol 4:462–7
29. Broders AC (1926) Carcinoma: grading and practical application. Arch Pathol 2:376–80
30. Weedon D, Strutton G (2002) Skin pathology, 2nd edn. Churchill Livingstone, London
31. Remmele W, Stegner HE (1987) Vorschlag zur einheitlichen definition eines immunoreaktiven score (IRS) für den immunohistochemischen Ostrogerezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologie 8:138–40
32. Karasawa M, Nishimura N, Nishimura H et al (1991) Localization of metallothionein in hair follicles of normal skin and the basal cell layer of hyperplastic epidermis: possible association with cell proliferation. J Invest Dermatol 97:97–100
33. Van den Oord JJ, De Ley M (1994) Distribution of metallothionein in normal and pathological human skin. Arch Dermatol Res 286:62–8
34. Borges Júnior PC, Ribeiro RL, Cardoso SV et al (2007) Metallothionein immunolocalization in actinic skin nonmelanoma carcinomas. Appl Immunohistochem Mol Morphol 15:165–9
35. Sundelin K, Jadner M, Norberg-Spaak L et al (1997) Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. Eur J Cancer 33:1860–4
36. Dutsch-Wicherek M, Popiela TJ, Klimek M et al (2005) Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and brest adenocarcinoma. Neuro Endocrinol Lett 26:567–74
37. Muramatsu Y, Hasegawa Y, Fukano H et al (2000) Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviours and chemotherapy responses. Anticancer Res 20:257–64
38. Goldmann T, Moorkamp A, Wiedorn KH et al (2001) The prognostic value of the expression of collagenase IV, cathepsin D and metallothionein in squamous cell carcinomas of the skin determined by immunohistochemistry. Arch Dermatol Res 293:115–120
39. Veness MJ (2007) High-risk cutaneous squamous cell carcinoma of the head and neck. J Biomed Biotechnol 2007(3):80572, Epub 2007 Apr 3
40. Son KD, Kim TJ, Lee YS et al (2008) Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol 97:615–620
41. Dziegiel P, Forgacz J, Suder E et al (2003) Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol Histopathol 18:401–7
42. Jayasurya A, Bay BH, Yap WM et al (2000) Proliferative potential in nasopharyngeal carcinoma: correlations with metallothionein expression and tissue zinc levels. Carcinogenesis 21:1809–12
43. Pastuszewski W, Dziegiel P, Krecicki T et al (2007) Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Res 27:335–42
44. Rossen K, Haerslev T, Hou-Jensen K et al (1997) Metallothionein expression in basaloid proliferations overlying dermatofibromas and basal cell carcinomas. Br J Dermatol 136:30–4